Wealthcare Advisory Partners LLC Intellia Therapeutics, Inc. Transaction History

Wealthcare Advisory Partners LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $129,056 - $255,532	-3,353 Closed	0 $0
Q1 2022 Apr 15, 2022	BUY	$58.27 - $118.99 $116 - $237	2 Added 0.06%	3,353 $244,000
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $25,089 - $34,451	-249 Reduced 6.92%	3,351 $396,000
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $88,687 - $118,442	-670 Reduced 15.69%	3,600 $483,000
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $97,408 - $259,056	1,600 Added 59.93%	4,270 $691,000
Q1 2021 Apr 30, 2021	BUY	$46.59 - $83.68 $124,395 - $223,425	2,670 New	2,670 $214,000
Q2 2020 Jul 29, 2020	SELL	$11.14 - $22.87 $33,085 - $67,923	-2,970 Closed	0 $0
Q1 2020 Apr 29, 2020	BUY	$9.44 - $15.58 $3,964 - $6,543	420 Added 16.47%	2,970 $36,000
Q4 2019 Jan 29, 2020	BUY	$10.43 - $17.67 $26,596 - $45,058	2,550 New	2,550 $37,000
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $148,363 - $187,613	-5,755 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $65,065 - $100,067	3,250 Added 129.74%	5,755 $157,000
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $48,672 - $87,549	2,505 New	2,505 $53,000

326

88.8M

673K

865K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.56B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Wealthcare Advisory Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Wealthcare Advisory Partners LLC with notifications on news.